Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for...
MCLEAN, VA / ACCESSWIRE / December 12, 2024 / Dr. Amir Bajoghli recently had the honor of presenting a comprehensive...
Celebrating a Culture of Collaboration and a Mission to Save Lives Through Data SAN DIEGO, CALIFORNIA / ACCESSWIRE / December...
CELLEV8 Launches First Post-GLP-1 Gummy Supplement: "SlimCell™" with Clinically Proven Ingredients to Compliment GLP-1 WELLINGTON, FL / ACCESSWIRE / December...
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / Haven House Luxury Sober Living is honored to announce its...
Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing...
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth...
GAT Sport®, a trailblazer in sports nutrition, is thrilled to announce the launch of Nitraflex® SPORT. Certified with Informed Sport,...
PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased...
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a...
Exclusive Non-Binding Letter of Intent signed with Target that has more than $40 million in revenue and positive EBITDA in...
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that...
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient...
BETHESDA, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) is proud to announce its plans...
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS...
Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”),...
In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV)In multiple preclinical...
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy...